Francesco Longo - Publications

Affiliations: 
NYU CNS, New York, NY, United States 

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Busch SE, Simmons DH, Gama E, Du X, Longo F, Gomez CM, Klann E, Hansel C. Overexpression of the autism candidate gene pathologically enhances olivo-cerebellar signaling in mice. Frontiers in Cellular Neuroscience. 17: 1219270. PMID 37545882 DOI: 10.3389/fncel.2023.1219270  0.531
2023 Longo F, Aryal S, Anastasiades PG, Maltese M, Baimel C, Albanese F, Tabor J, Zhu JD, Oliveira MM, Gastaldo D, Bagni C, Santini E, Tritsch NX, Carter AG, Klann E. Cell-type-specific disruption of cortico-striatal circuitry drives repetitive patterns of behavior in fragile X syndrome model mice. Cell Reports. 42: 112901. PMID 37505982 DOI: 10.1016/j.celrep.2023.112901  0.692
2023 Mercaldo V, Vidimova B, Gastaldo D, Fernández E, Lo AC, Cencelli G, Pedini G, De Rubeis S, Longo F, Klann E, Smit AB, Grant SGN, Achsel T, Bagni C. Altered striatal actin dynamics drives behavioral inflexibility in a mouse model of fragile X syndrome. Neuron. PMID 36996810 DOI: 10.1016/j.neuron.2023.03.008  0.558
2022 Kalinowska M, van der Lei MB, Kitiashvili M, Mamcarz M, Oliveira MM, Longo F, Klann E. Deletion of Fmr1 in parvalbumin-expressing neurons results in dysregulated translation and selective behavioral deficits associated with fragile X syndrome. Molecular Autism. 13: 29. PMID 35768828 DOI: 10.1186/s13229-022-00509-2  0.598
2022 Gross C, Banerjee A, Tiwari D, Longo F, White AR, Allen AG, Schroeder-Carter LM, Krzeski JC, Elsayed NA, Puckett R, Klann E, Rivero RA, Gourley SL, Bassell GJ. Correction to: Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 35701551 DOI: 10.1038/s41386-022-01345-x  0.516
2022 Allen M, Huang BS, Notaras MJ, Lodhi A, Barrio-Alonso E, Lituma PJ, Wolujewicz P, Witztum J, Longo F, Chen M, Greening DW, Klann E, Ross ME, Liston C, Colak D. Spontaneous generation of ASD astrocytes. Molecular Psychiatry. 27: 2369. PMID 35618836 DOI: 10.1038/s41380-022-01606-7  0.445
2022 Allen M, Huang BS, Notaras MJ, Lodhi A, Barrio-Alonso E, Lituma PJ, Wolujewicz P, Witztum J, Longo F, Chen M, Greening DW, Klann E, Ross ME, Liston C, Colak D. Astrocytes derived from ASD individuals alter behavior and destabilize neuronal activity through aberrant Ca signaling. Molecular Psychiatry. PMID 35365802 DOI: 10.1038/s41380-022-01486-x  0.531
2021 Viaro R, Longo F, Vincenzi F, Varani K, Morari M. L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter. Brain Research. 147583. PMID 34284020 DOI: 10.1016/j.brainres.2021.147583  0.439
2021 Longo F, Klann E. Reciprocal control of translation and transcription in autism spectrum disorder. Embo Reports. e52110. PMID 33977633 DOI: 10.15252/embr.202052110  0.505
2021 Aryal S, Longo F, Klann E. Genetic removal of p70 S6K1 corrects coding sequence length-dependent alterations in mRNA translation in fragile X syndrome mice. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33906942 DOI: 10.1073/pnas.2001681118  0.661
2021 Longo F, Mancini M, Ibraheem PL, Aryal S, Mesini C, Patel JC, Penhos E, Rahman N, Mamcarz M, Santini E, Rice ME, Klann E. Cell-type-specific disruption of PERK-eIF2α signaling in dopaminergic neurons alters motor and cognitive function. Molecular Psychiatry. PMID 33879865 DOI: 10.1038/s41380-021-01099-w  0.671
2021 Oliveira MM, Lourenco MV, Longo F, Kasica NP, Yang W, Ureta G, Ferreira DDP, Mendonça PHJ, Bernales S, Ma T, De Felice FG, Klann E, Ferreira ST. Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer's disease. Science Signaling. 14. PMID 33531382 DOI: 10.1126/scisignal.abc5429  0.617
2020 Shrestha P, Ayata P, Herrero-Vidal P, Longo F, Gastone A, LeDoux JE, Heintz N, Klann E. Cell-type-specific drug-inducible protein synthesis inhibition demonstrates that memory consolidation requires rapid neuronal translation. Nature Neuroscience. PMID 31959934 DOI: 10.1038/S41593-019-0568-Z  0.649
2019 Notaras M, Allen M, Longo F, Volk N, Toth M, Li Jeon N, Klann E, Colak D. UPF2 leads to degradation of dendritically targeted mRNAs to regulate synaptic plasticity and cognitive function. Molecular Psychiatry. PMID 31636381 DOI: 10.1038/S41380-019-0547-5  0.587
2019 Mercatelli D, Bolognesi P, Frassineti M, Pisanò CA, Longo F, Shimshek DR, Morari M. Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes. Pharmacology Research & Perspectives. 7: e00484. PMID 31149340 DOI: 10.1002/Prp2.484  0.575
2019 Park J, Longo F, Park SJ, Lee S, Bae M, Tyagi R, Han JH, Kim S, Santini E, Klann E, Snyder SH. Inositol polyphosphate multikinase mediates extinction of fear memory. Proceedings of the National Academy of Sciences of the United States of America. PMID 30692248 DOI: 10.1073/Pnas.1812771116  0.573
2018 Gross C, Banerjee A, Tiwari D, Longo F, White AR, Allen AG, Schroeder-Carter LM, Krzeski JC, Elsayed NA, Puckett R, Klann E, Rivero RA, Gourley SL, Bassell GJ. Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30061744 DOI: 10.1038/S41386-018-0150-5  0.607
2017 Santini E, Huynh TN, Longo F, Koo SY, Mojica E, D'Andrea L, Bagni C, Klann E. Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice. Science Signaling. 10. PMID 29114037 DOI: 10.1126/Scisignal.Aan0665  0.717
2017 Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I, Berti G, Mabrouk OS, Kennedy RT, Shimshek DR, Varani K, Bubacco L, Greggio E, Morari M. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice. Acta Neuropathologica Communications. 5: 22. PMID 28292328 DOI: 10.1186/S40478-017-0426-8  0.72
2017 Rimessi A, Pavan C, Ioannidi E, Nigro F, Morganti C, Brugnoli A, Longo F, Gardin C, Ferroni L, Morari M, Vindigni V, Zavan B, Pinton P. Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28128334 DOI: 10.1038/Npp.2017.20  0.524
2016 Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. Neurobiology of Disease. PMID 26804029 DOI: 10.1016/J.Nbd.2016.01.016  0.577
2015 Cristino L, Luongo L, Squillace M, Paolone G, Mango D, Piccinin S, Zianni E, Imperatore R, Iannotta M, Longo F, Errico F, Vescovi AL, Morari M, Maione S, Gardoni F, et al. d-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain. Neurobiology of Aging. 36: 1890-902. PMID 25771393 DOI: 10.1016/J.Neurobiolaging.2015.02.003  0.506
2015 Ravani L, Sarpietro MG, Esposito E, Di Stefano A, Sozio P, Calcagno M, Drechsler M, Contado C, Longo F, Giuffrida MC, Castelli F, Morari M, Cortesi R. Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity. Materials Science & Engineering. C, Materials For Biological Applications. 48: 294-300. PMID 25579926 DOI: 10.1016/J.Msec.2014.12.014  0.489
2014 Longo F, Russo I, Shimshek DR, Greggio E, Morari M. Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiology of Disease. 71: 62-73. PMID 25107341 DOI: 10.1016/J.Nbd.2014.07.013  0.559
2014 Cirnaru MD, Marte A, Belluzzi E, Russo I, Gabrielli M, Longo F, Arcuri L, Murru L, Bubacco L, Matteoli M, Fedele E, Sala C, Passafaro M, Morari M, Greggio E, et al. LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Frontiers in Molecular Neuroscience. 7: 49. PMID 24904275 DOI: 10.3389/Fnmol.2014.00049  0.553
2014 Bonito-Oliva A, Pignatelli M, Spigolon G, Yoshitake T, Seiler S, Longo F, Piccinin S, Kehr J, Mercuri NB, Nisticò R, Fisone G. Cognitive impairment and dentate gyrus synaptic dysfunction in experimental parkinsonism. Biological Psychiatry. 75: 701-10. PMID 23541633 DOI: 10.1016/J.Biopsych.2013.02.015  0.323
2006 Oliveira MM, Lourenco MV, Longo F, De Felice FG, Klann E, Ferreira ST. P3-171: TARGETING TRANSLATION IMPAIRMENT TO RESTORE COGNITIVE DEFICITS IN ALZHEIMER'S DISEASE MODELS Alzheimer's & Dementia. 14: P1133-P1133. DOI: 10.1016/J.Jalz.2018.06.1529  0.518
Show low-probability matches.